Pradeep Chaluvally-Raghavan, PhD
Dr. Pradeep Chaluvally-Raghavan received Ph.D. degree in 2006 from the University of Calicut, India where he focused on the role NF-kappa B activation and pro-inflammatory cytokine genes in melanoma models. After completion of graduate school, he moved to the laboratory of Dr. Yosef Yarden at the Weizmann Institute of Sciences, Israel for postdoctoral research. In Dr. Yarden’s laboratory, he studied the role of epidermal growth factor receptor (EGFR) family members in breast cancer progression.
During this period, he identified that NOTCH3 and NOTCH3-associated genes deregulate the growth of mammary epithelial cells and promote the transition of normal mammary duct to Ductal Carcinoma In Situ (DCIS) in breast cancer models. Further, during this transition phase of DCIS to invasive cancer, he characterized the role of three distinct pathways hypoxia, integrin and bone morphogenetic protein (BMP) signaling pathways. In 2010, he joined the lab of Dr. Gordon Mills in the Department of Systems Biology at the MD Anderson Cancer Center. In Mills lab, he focused on genomic aberrations such as gene mutation or copy number variation (CNVs), and its effect on downstream signaling pathways in breast and ovarian cancer. In 2016, he was recruited as a tenure track Assistant Professor to the Department of Obstetrics and Gynecology at the Medical College of Wisconsin. In the current position Dr. Chaluvally continues his post-doctoral work initiated in the Mills lab, and extends this research into other areas of non-coding RNA biology. Specifically, he is studying the role of non-coding RNA in mediating transcriptional and post-transcriptional regulation of gene expression. Over the last 6 years, he has made major scientific contributions to our understanding of the role of non-coding RNA aberrations as part of the CNVs in cancer.
Dr. Chaluvally-Raghavan completed his Ph.D from the University of Calicut in India. During his graduate training his research… Read More ›